NATCO Pharma Limited (BOM:524816)
813.20
-5.80 (-0.71%)
At close: Sep 16, 2026
NATCO Pharma Revenue
NATCO Pharma had revenue of 7.35B INR in the quarter ending June 30, 2026, a decrease of -44.68%. This brings the company's revenue in the last twelve months to 34.85B, down -20.73% year-over-year. In the fiscal year ending March 31, 2026, NATCO Pharma had annual revenue of 40.82B, down -7.90%.
Revenue (ttm)
34.85B
Revenue Growth
-20.73%
P/S Ratio
4.21
Revenue / Employee
7.86M
Employees
4,433
Market Cap
146.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 40.82B | -3.50B | -7.90% |
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 86.08B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 35.75B |
| AstraZeneca Pharma India | 24.32B |
| Caplin Point Laboratories | 22.87B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
NATCO Pharma News
- 26 days ago - Natco’s AP formulations unit gets USFDA Form 483 with 4 observations - The Times of India
- 4 weeks ago - NATCO Pharma Transcript: Q1 26/27 - Transcripts
- 4 weeks ago - NATCO Pharma Quarterly report: Q1 2027 - Filings
- 4 weeks ago - NATCO Pharma Slides: Q1 2027 - Filings
- 6 weeks ago - NATCO Pharma Slides: Investor presentation - Filings
- 2 months ago - NATCO Pharma approves Rs 1,069 crore investment to raise Adcock Ingram stake to 49% - Business Upturn
- 2 months ago - Pharma sector stocks today, July 8: Natco Pharma falls 1.90%m Zydus Life surge 1.71%, Strides Pharma down 1.33% - Business Upturn
- 2 months ago - Pharma sector stocks rally today, June 23: IPCA Labs up 2.54%, Dr. Reddys Lab gains 2.47%, Natco Pharma rises 2.45% - Business Upturn